Pangolins occupy a singular and grim position in conservation discourse. Often described as the most heavily trafficked mammals on Earth, the eight recognized species, four in Asia and four in Africa, are protected under the Convention on International Trade in Endangered Species, with all populations listed on Appendix I, the strictest category of control. Trade in Appendix I species requires both import and export permits, and commercial trade is generally prohibited. Despite these protections, demand persists, driven overwhelmingly by scales used in traditional medicine systems across Asia and Africa and among diaspora communities worldwide. The scales are composed of keratin, the same protein found in human fingernails, yet they are ground into powders, brewed into teas, or prescribed whole in the belief that they can treat ailments ranging from skin conditions to circulatory problems. Beyond scales, nearly every part of a pangolin carries some purported use: bones, claws, eyes, fat, blood, and whole skins appear in medicinal, spiritual, and cultural practices, while the meat is prized as a delicacy in some regions.

Whole skins, however, occupy a less common niche in the trafficking record. Most seizures involve scales, sometimes by the ton, stripped from thousands of animals and packed into shipping containers. An intact skin suggests a different supply chain and a different end user. Rather than industrial-scale processing for pharmaceutical markets, a whole skin points toward individual practitioners, ritual specialists, or collectors who need the recognizable form of the animal itself. This distinction matters for enforcement agencies with finite resources: a container of scales represents volume and profit, while a single skin in a passenger shipment may represent a personal, culturally embedded practice that enforcement alone cannot extinguish.

The forensic examination began with the fundamentals. Morphological analysis, the oldest tool in the wildlife forensics toolkit, relies on the trained eye comparing evidence against reference specimens and published descriptions. The first suspected pangolin skin displayed features consistent with the family: overlapping scales with longitudinal ridges, a diamond pattern on the underside, and the characteristic taper of scales along the tail. The three-cusped scales proved diagnostic. Among African pangolins, the White-bellied Tree Pangolin, Phataginus tricuspis, bears scales with this distinctive trident shape, a feature reflected in its species name. The presence of short, pale hairs along the belly further supported identification, since tree-dwelling pangolins retain some fur on their undersides while their ground-dwelling cousins are more fully armored. The specimen’s condition, flattened, odoriferous, and hosting dead dermestid beetle larvae, told a story of crude preparation and prolonged storage, consistent with a skin harvested, treated minimally, and shipped without professional taxidermic care.

The second suspected pangolin skin told a different story upon close inspection. Its scales were unnaturally uniform in size and roughly rectangular, lacking the organic variation of true pangolin armor. A reddish-brown varnish had been applied after assembly, pooling in ways that revealed the item had been painted as a finished object rather than colored during the animal’s life. The backing was fabric. Whatever this object was meant to represent, it was manufactured, not harvested. Subsequent chemical analysis using x-ray fluorescence spectrometry, a technique that bombards a sample with x-rays and reads the characteristic secondary emissions to identify elemental composition, and genetic sequencing revealed the truth: the scales came from Atlantic Tarpon, Megalops atlanticus, a large silvery fish of coastal Atlantic waters. Tarpon scales are large, firm, and plate-like, making them plausible raw material for imitation pangolin armor once cut, shaped, and dyed.

The counterfeit lion head was, if anything, more brazen. Constructed over a carved block of hard foam, it featured plastic eyes, plastic teeth with an anatomically impossible count of five incisors where a true carnivoran has six, painted whisker follicles, and fur seams glued together with patches of hair concealing the joins. Styrofoam peeked through chipped paint on the cheek teeth. Genetic testing identified the fur as domestic goat. Yet the object was clearly made to deceive at a glance, and in a marketplace or ritual context where a lion head carries symbolic weight, a convincing silhouette and mane-like fur might suffice. Lions are protected under CITES, with Indian populations on Appendix I and all others on Appendix II, so a genuine lion head would require export documentation at minimum. A goat in costume requires nothing, which is precisely the economic logic of counterfeiting.

Counterfeiting in wildlife trade is not new, but it is understudied. Fakes can serve multiple functions: they allow sellers to meet demand when genuine products are scarce or expensive, they reduce risk for traffickers who can pass off cheap substitutes, and in some cases buyers may be complicit, purchasing a plausible token rather than a costly authentic item. The presence of both a genuine pangolin skin and a counterfeit one in the same shipment raises intriguing questions. Was the buyer deceived about one or both? Was the shipment a test of what sells? Or do different market segments exist, with authentic items commanding premium prices while fakes serve budget-conscious customers? The forensic record alone cannot answer these questions, but documenting the phenomenon alerts enforcement agencies and researchers that fraud, not just trafficking, characterizes parts of this trade.

The geographic reasoning in this case demonstrates how even modest investigative resources can narrow a shipment’s likely origin. The White-bellied Tree Pangolin ranges across West and Central Africa’s forest zones. Western Harnessed Bushbucks, identified from the hides in the shipment, occupy a more restricted range within coastal West Africa. Atlantic Tarpon spawn and juveniles inhabit coastal waters off West Africa, and domestic goats are, of course, ubiquitous. The intersection of all these species’ ranges points toward the coastal West African region, and the air waybill originating in Sierra Leone corroborated that inference. Sierra Leone appears on lists of both source and transit countries for illegal wildlife trade, and its position along the Upper Guinean forest region places it squarely within the overlap zone the species distributions suggest. This convergence of independent lines of evidence, morphology, chemistry, genetics, and shipping documentation, exemplifies the corroboration that gives forensic conclusions their weight.

The intended use of these items likely lies in traditional West African medicinal or religious practices. Cowrie shells, long significant in West African spiritual and economic history, and drums made from ungulate hides fit this context, as do bushbuck skins and pangolin parts, which appear in various regional traditions. If the shipment indeed served West African traditional practices within the United States, it may signal a demand stream distinct from the well-documented Asian medicinal trade that dominates pangolin trafficking statistics. Demand-reduction strategies must be tailored to the communities that generate demand, and a strategy designed for Asian medicine markets may resonate poorly, or offensively, with West African religious practitioners. Understanding the cultural context is therefore not an academic luxury but a practical prerequisite for interventions that are both effective and respectful.

The destruction of the drums and bushbuck hides under Centers for Disease Control and Prevention guidelines highlights another dimension of wildlife importation that receives less public attention: zoonotic risk. Untreated hides from hoofed stock can harbor Bacillus anthracis, the bacterium responsible for anthrax, which persists in animal products and poses genuine hazard to handlers, inspectors, and end users. Anthrax is endemic in parts of sub-Saharan Africa, and hides that have not undergone proper tanning or sterilization can carry viable spores across continents. The precautionary destruction of these items, photographed and documented first, reflects standard biosecurity protocol and underscores that wildlife trafficking endangers public health as well as biodiversity.

Methodologically, this case study champions a pragmatic philosophy. Forensic laboratories typically operate under tight budgets, and species identification alone often suffices to support prosecution. Investing in geographic provenancing, reference collections, and validated genetic markers for origin assignment is expensive. Yet the authors demonstrate that by considering every item in a shipment, including the legal, common, and counterfeit ones, investigators can extract intelligence about origin, purpose, and emerging trends without additional cost. A goat head dressed as a lion, a tarpon disguised as a pangolin, and a genuine tree pangolin skin together sketch a portrait of a trade route and a market that no single item could provide.

For conservationists, the broader lesson is that the wildlife trade is a moving target. As enforcement tightens around the most conspicuous flows, such as bulk pangolin scales, demand may fragment into smaller shipments, substitute species, and fabricated products. Detection requires not only better technology but broader thinking: forensic scientists who can recognize a fake, ecologists who can map where species overlap, and social scientists who can interpret why a package crossed an ocean. This single fishy pangolin, as the study’s title wryly acknowledges, carries within its counterfeit scales a reminder that protecting the world’s most trafficked mammal demands vigilance against both the trade in the real and the trade in the false.

Subject of Research: Forensic insights from a fishy pangolin on the trade in real and fake whole pangolin skins

Article Title: Forensic insights from a fishy pangolin on the trade in real and fake whole pangolin skins

Article References: Tinsman, J., Hamlin, B. C., Goldman, J.-M., Chaffra, A. S., Straughan, D. J., & Espinoza, E. (2026). Forensic insights from a fishy pangolin on the trade in real and fake whole pangolin skins. Discover Conservation, 3(1), Article 34. https://doi.org/10.1007/s44353-026-00100-3

Image Credits: AI Generated

DOI: 10.1007/s44353-026-00100-3

Keywords: Forensic, insights, fishy, pangolin, trade, real, fake, whole, skins, scientific research

The proposed framework addresses a central paradox in radioimmunotherapy. Radiation is increasingly understood as an immunological treatment as well as a physical one, but clinical responses to combinations of radiation and checkpoint inhibitors remain inconsistent. Some patients experience immune effects beyond the irradiated tumor, while others show little durable benefit. Even when immune remodeling occurs, it may fade as the tumor’s suppressive defenses return. The perspective, by Zhusheng Huang, Xueyu Chen, Simin Xia, Lianhui Wang and colleagues, presents insufficient immune amplification as a major bottleneck. Its emphasis is not on claiming that radiation fails to activate immunity, but on explaining why the initial activation frequently does not mature into systemic, long-term tumor control.

Radiation can initiate this process through several linked biological events. Damage to tumor DNA kills cancer cells and can produce immunogenic cell death, a form of cellular destruction that exposes or releases signals recognized by the immune system. Dying cells may display calreticulin on their surfaces and release ATP and HMGB1, molecular cues that help dendritic cells mature and capture tumor-associated antigens. Those dendritic cells can then travel to lymph nodes, present tumor fragments to T cells, and begin the process of generating tumor-directed immunity. Radiation also causes DNA to accumulate in the cytoplasm, where the cGAS–STING pathway can detect it and stimulate production of type I interferons, signaling molecules that support innate immune activation and T-cell priming.

That response has built-in limits. Very high radiation doses delivered in a single fraction can induce the DNA-degrading enzyme TREX1, which removes cytosolic DNA and weakens cGAS–STING signaling. Radiation can also produce a counter-response inside the tumor microenvironment. Regulatory T cells and myeloid-derived suppressor cells may accumulate, macrophages can adopt an immunosuppressive state, and hypoxia can reinforce conditions that make immune attack more difficult. Tumor cells may increase checkpoint molecules such as PD-L1, while radiation exposure to circulating lymphocytes or tumor-draining lymph nodes can reduce the immune cells needed for effective priming. The net result depends on tumor type, immune condition, radiation dose, schedule, treated volume, and the timing of each treatment component.

Checkpoint inhibitors address only part of this problem. Drugs that block PD-1 or PD-L1 can restore the activity of exhausted or restrained T cells, but they do not necessarily solve upstream failures in antigen release, antigen presentation, innate sensing, or immune-cell trafficking. In an immune-cold tumor, radiation may provide only a short-lived spark, leaving too little inflammatory information for dendritic cells and T cells to build a durable response. The authors therefore position nano-immunoadjuvants between radiation and checkpoint blockade. Their role would be to increase the strength, duration, and spatial reach of signals initiated by radiation while weakening the biological barriers that prevent immune cells from entering or functioning within the tumor.

In this view, a nano-immunoadjuvant is a programmable immune amplification system rather than a passive drug carrier. Its composition and physical properties could be designed around a specific bottleneck. Platforms that activate cGAS–STING might compensate for inadequate innate sensing and enhance interferon signaling. Other systems could relieve hypoxia, promote reactive oxygen species and immunogenic cell death, encourage dendritic-cell maturation, or reprogram suppressive myeloid cells. Nanomaterials may also be designed to respond to radiation-associated conditions such as reactive oxygen species, acidic pH, low oxygen, or enzyme activity, releasing an immune-active cargo at a selected location or time. The goal is to convert a tumor with limited immune visibility into one more accessible to adaptive immune attack.

Some elements of this approach already have translational precedents, although the perspective distinguishes immune amplification from conventional radiosensitization. Hafnium oxide nanoparticles such as NBTXR3 have been evaluated as radioenhancers, increasing radiation energy deposition and local tumor control. Other experimental platforms, including two-dimensional risedronate–manganese nanobelts, are described as combining radiosensitization with hypoxia modulation and cGAS–STING activation. Such designs illustrate how one material might connect local radiation damage with broader immune signaling. The authors do not suggest that multifunctional nanoparticles are automatically superior. Instead, they argue that a platform should be matched to the dominant biological barrier in a particular tumor, with a clear mechanism linking its properties to the radiation regimen.

Radiation scheduling will be crucial to that design. Hypofractionated treatment and stereotactic body radiotherapy can stimulate type I interferon responses, but excessively high doses may activate TREX1 and suppress the pathway they initially trigger. Conventional fractionation may provide repeated waves of antigen release, while exposing circulating lymphocytes and immune-relevant lymph nodes over a longer period. Altering the timing of lymph-node irradiation may preserve immune function, and studies cited in the perspective indicate that the sequence of radiation, checkpoint blockade, and immune activation can influence outcomes. There is no universally immunogenic schedule. Instead, fraction size, total dose, treatment duration, target volume, nanoparticle delivery, and checkpoint inhibition may need to be optimized together as interdependent parts of programmable radioimmunotherapy.

Nano-immunoadjuvants are one of several possible ways to reinforce radiation-induced immunity. Oncolytic viruses can combine selective tumor-cell lysis with inflammatory antigen release, while pattern-recognition receptor agonists can activate defined innate pathways. Cytokines can provide powerful stimulation, though systemic toxicity and short exposure may limit their use; targeted interleukin-2 complexes are being investigated in preclinical combinations with radiation and PD-1 blockade. Epigenetic drugs may reverse immunosuppressive transcriptional programs, but broad effects can create additional risks. These approaches are complementary, and the most appropriate choice may depend on whether the limiting factor is antigen availability, innate sensing, T-cell expansion, immune-cell trafficking, hypoxia, or suppressive myeloid activity. Nanoparticles could potentially combine several functions, but every added function also increases complexity.

That complexity is among the largest obstacles to clinical translation. Multifunctional particles can require multistep synthesis, surface modification, drug loading, and stimulus-responsive components, making consistent control of size, composition, stability, sterility, and biological activity difficult at manufacturing scale. Regulators may also need to evaluate a product simultaneously as a drug, biomaterial, delivery vehicle, imaging agent, and radiation enhancer, including its degradation, tissue retention, immunogenicity, pharmacokinetics, and radiation-dependent behavior. Patient selection presents another challenge. Useful indicators may include tumor immune phenotype, PD-L1 expression, lymphocyte abundance, myeloid-cell composition, hypoxia, antigen-presentation capacity, cGAS–STING competence, and changes in circulating immune cells. No single biomarker is likely to capture all these processes, so tissue, blood, and imaging measurements may need to be integrated.

The perspective ultimately calls for simpler, mechanism-guided systems rather than increasingly elaborate nanoparticles without a defined biological purpose. Clinical trials will need to measure pharmacodynamic effects and immune kinetics, not just changes visible on scans. They must also account for human tumor heterogeneity, metastatic disease, prior therapies, clinically realistic radiation schedules, immune-cell exposure, nanoparticle distribution, and organ-specific toxicity. The proposed “trigger–amplify–sustain” model offers a way to organize those questions: radiation supplies the initial spatial signal, the nano-immunoadjuvant strengthens and redirects it, and checkpoint blockade helps maintain antitumor T-cell function. Whether that sequence can produce reliable, durable benefit remains to be established, but the framework shifts radioimmunotherapy toward deliberate immune engineering rather than empirical combination treatment.

Evidence that radiation can influence disease beyond the treatment field is emerging from clinical as well as laboratory observations. In metastatic non-small-cell lung cancer, stereotactic body radiotherapy combined with pembrolizumab was associated with systemic immune changes, including stronger interferon signaling and expansion of tumor-reactive T-cell clones. Notably, measurable benefit was reported even among patients with features often linked to limited response to immunotherapy, such as low tumor mutational burden or absent PD-L1 expression. These findings support the idea that radiation can broaden immune recognition, while also underscoring that immune effects outside the irradiated lesion are not guaranteed.

The distinction between immune initiation and immune durability has practical implications for trial design. Tumor shrinkage alone may not reveal whether a nano-immunoadjuvant has improved antigen presentation, innate sensing, or immune-cell recruitment. Pharmacodynamic studies could therefore examine interferon-related signals, dendritic-cell activation, tumor-reactive T-cell clonotypes, and changes in suppressive myeloid populations alongside conventional imaging. Sampling blood and, when feasible, tumor tissue may help determine whether a treatment effect is confined to the irradiated site or accompanied by broader immune remodeling.

Biomarker development will also need to account for pathway competence rather than relying on a single marker. A tumor may contain antigens yet remain poorly responsive because dendritic cells cannot efficiently cross-present them, because cGAS–STING signaling is impaired, or because hypoxia and suppressive myeloid cells block lymphocyte activity. Conversely, a patient with low PD-L1 expression may still benefit if radiation and immune amplification generate new tumor-reactive clones. This makes functional measurements—such as changes in interferon activity or clonotype expansion—potentially complementary to baseline staining and genomic classifications.

The proposed strategy therefore remains a testable therapeutic hypothesis, not a universal solution. Its success will depend on matching the nano-immunoadjuvant’s activity to the dominant immune deficit, coordinating delivery with a radiation schedule that preserves immune function, and demonstrating that amplified signals translate into durable control of untreated disease. Carefully designed studies could clarify which patients need more antigen release, stronger innate activation, improved trafficking, or relief from suppressive feedback.

Subject of Research: Nano-immunoadjuvants for amplifying radiotherapy-induced antitumor immunity

Article Title: Radiotherapy-induced immunity is real but incomplete: nano-immunoadjuvants as immune amplifiers in radioimmunotherapy

Article References: Huang, Z., Chen, X., Xia, S., & Wang, L. (2026). Radiotherapy-induced immunity is real but incomplete: nano-immunoadjuvants as immune amplifiers in radioimmunotherapy. Clinical Cancer Bulletin, 5(1), Article 17. https://doi.org/10.1007/s44272-026-00070-6

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00070-6

Keywords: radiotherapy, immunotherapy, nano-immunoadjuvants, radioimmunotherapy, tumor microenvironment, cGAS-STING, immune checkpoint blockade, cancer nanomedicine, Radiotherapy-induced, immunity, real, incomplete